Investment in expanding production is beginning to show results! Eli Lilly's supply tightness in Japan is easing, and shipment control is finally lifted

Eli Lilly has made a huge investment to expand production capacity, which is starting to show results. Due to supply shortages, the company implemented shipping controls in Japan last year, but these have now been lifted. The weight-loss drugs from Eli Lilly and its competitor Novo Nordisk are widely popular globally, with demand continuously increasing. It is expected that by the end of this decade, a market worth $80 billion will be created. Eli Lilly is investing in expanding the capacity of its Kobe plant and increasing its investment in the production base in Lebanon, Indiana. At the same time, the company is restricting the listing of these drugs outside the United States